{"product_id":"injectable-yk-11-700mg-vial","title":"Injectable YK-11 700mg vial","description":"\u003cp\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                        \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003eFOR HUMAN \u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eCONSUMPTION\u003cmeta charset=\"UTF-8\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"39\" data-end=\"610\"\u003eYK-11 is a \u003cstrong data-start=\"83\" data-end=\"141\"\u003esteroidal selective androgen-receptor modulator (SARM)\u003c\/strong\u003e first described in academic screens of AR-active compounds. Unlike many non-steroidal SARMs, YK-11 behaves as a \u003cstrong data-start=\"254\" data-end=\"276\"\u003epartial AR agonist\u003c\/strong\u003e that strongly \u003cstrong data-start=\"291\" data-end=\"325\"\u003eup-regulates follistatin (FST)\u003c\/strong\u003e, thereby \u003cstrong data-start=\"335\" data-end=\"399\"\u003eantagonizing myostatin\/activin-A (ActRIIB–SMAD2\/3) signaling\u003c\/strong\u003e—a pathway that restrains skeletal-muscle growth. The compound has \u003cstrong data-start=\"466\" data-end=\"493\"\u003eno approved medical use\u003c\/strong\u003e, \u003cstrong data-start=\"495\" data-end=\"520\"\u003eno published human PK\u003c\/strong\u003e, and remains a \u003cstrong data-start=\"536\" data-end=\"557\"\u003eresearch chemical\u003c\/strong\u003e. It is \u003cstrong data-start=\"565\" data-end=\"588\"\u003eprohibited in sport\u003c\/strong\u003e as an anabolic agent.\u003c\/p\u003e\n\u003chr data-start=\"612\" data-end=\"615\"\u003e\n\u003ch3 data-start=\"617\" data-end=\"673\"\u003eAdditional Benefits of YK-11 Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"675\" data-end=\"2729\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"675\" data-end=\"703\"\u003e\n\u003ctr data-start=\"675\" data-end=\"703\"\u003e\n\u003cth data-start=\"675\" data-end=\"685\" data-col-size=\"md\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-start=\"685\" data-end=\"703\" data-col-size=\"xl\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"714\" data-end=\"2729\"\u003e\n\u003ctr data-start=\"714\" data-end=\"982\"\u003e\n\u003ctd data-start=\"714\" data-end=\"760\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"716\" data-end=\"759\"\u003e1 Myostatin–follistatin axis modulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"760\" data-end=\"982\" data-col-size=\"xl\"\u003eYK-11 increases \u003cstrong data-start=\"778\" data-end=\"793\"\u003efollistatin\u003c\/strong\u003e expression via AR-dependent transcription, \u003cstrong data-start=\"837\" data-end=\"871\"\u003eneutralizing myostatin\/activin\u003c\/strong\u003e and de-repressing hypertrophy programs. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Biochem Biophys Res Commun; J Steroid Biochem Mol Biol\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"983\" data-end=\"1228\"\u003e\n\u003ctd data-start=\"983\" data-end=\"1038\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"985\" data-end=\"1037\"\u003e2 Myogenic differentiation \u0026amp; hypertrophy (cells)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1038\" data-end=\"1228\" data-col-size=\"xl\"\u003eIn \u003cstrong data-start=\"1043\" data-end=\"1062\"\u003eC2C12 myoblasts\u003c\/strong\u003e, YK-11 accelerates \u003cstrong data-start=\"1082\" data-end=\"1103\"\u003emyotube formation\u003c\/strong\u003e, enlarges \u003cstrong data-start=\"1114\" data-end=\"1134\"\u003emyotube diameter\u003c\/strong\u003e, and up-regulates \u003cstrong data-start=\"1153\" data-end=\"1170\"\u003eMyoD\/Myogenin\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Skeletal Muscle; Molecular Endocrinology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1229\" data-end=\"1429\"\u003e\n\u003ctd data-start=\"1229\" data-end=\"1275\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1231\" data-end=\"1274\"\u003e3 mTOR anabolism \/ anti-catabolic shift\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1275\" data-end=\"1429\" data-col-size=\"xl\"\u003eDownstream of myostatin blockade: \u003cstrong data-start=\"1311\" data-end=\"1325\"\u003e↑ mTOR\/S6K\u003c\/strong\u003e, \u003cstrong data-start=\"1327\" data-end=\"1353\"\u003e↓ FoxO → ↓ MAFbx\/MuRF1\u003c\/strong\u003e, favoring net protein synthesis. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;AJP-Endocrinology; FASEB J\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1430\" data-end=\"1634\"\u003e\n\u003ctd data-start=\"1430\" data-end=\"1470\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1432\" data-end=\"1469\"\u003e4 Osteoblast signaling (in vitro)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1470\" data-end=\"1634\" data-col-size=\"xl\"\u003eSteroidal AR agonism \u003cstrong data-start=\"1493\" data-end=\"1532\"\u003epromotes osteoblast differentiation\u003c\/strong\u003e (↑ RUNX2\/OSX) and mineralization markers in cell systems—preclinical only. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Bone; JBMR\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1635\" data-end=\"1862\"\u003e\n\u003ctd data-start=\"1635\" data-end=\"1678\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1637\" data-end=\"1677\"\u003e5 Satellite-cell milieu (hypothesis)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1678\" data-end=\"1862\" data-col-size=\"xl\"\u003eFollistatin up-shift \u003cstrong data-start=\"1701\" data-end=\"1748\"\u003emay support Pax7⁺ satellite-cell activation\u003c\/strong\u003e and repair kinetics; direct in-vivo evidence for YK-11 is limited. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Development; Stem Cell Reports\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1863\" data-end=\"2099\"\u003e\n\u003ctd data-start=\"1863\" data-end=\"1901\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1865\" data-end=\"1900\"\u003e6 Fat-mass reduction (indirect)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1901\" data-end=\"2099\" data-col-size=\"xl\"\u003eAnabolism and myostatin restraint \u003cstrong data-start=\"1937\" data-end=\"1976\"\u003eshift partitioning toward lean mass\u003c\/strong\u003e with secondary fat-mass signals in models; \u003cstrong data-start=\"2020\" data-end=\"2062\"\u003eno robust in-vivo YK-11 body-comp data\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Metabolism; Obesity\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2100\" data-end=\"2333\"\u003e\n\u003ctd data-start=\"2100\" data-end=\"2153\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2102\" data-end=\"2152\"\u003e7 Tendon\/connective-tissue remodeling (theory)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2153\" data-end=\"2333\" data-col-size=\"xl\"\u003eMyostatin blockade can modify \u003cstrong data-start=\"2185\" data-end=\"2201\"\u003eECM\/collagen\u003c\/strong\u003e programs; clinical implications for \u003cstrong data-start=\"2238\" data-end=\"2268\"\u003etendon stiffness\/fragility\u003c\/strong\u003e remain theoretical. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;J Orthop Res; Matrix Biology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2334\" data-end=\"2542\"\u003e\n\u003ctd data-start=\"2334\" data-end=\"2356\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2336\" data-end=\"2355\"\u003e8 Rehab synergy\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2356\" data-end=\"2542\" data-col-size=\"xl\"\u003eConceptually \u003cstrong data-start=\"2371\" data-end=\"2383\"\u003eadditive\u003c\/strong\u003e with resistance training\/nutrition due to AR + myostatin pathways; data for YK-11 specifically are \u003cstrong data-start=\"2483\" data-end=\"2503\"\u003eabsent in humans\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Sports Med; J Physiol\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2543\" data-end=\"2729\"\u003e\n\u003ctd data-start=\"2543\" data-end=\"2576\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2545\" data-end=\"2575\"\u003e9 Doping-control relevance\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2576\" data-end=\"2729\" data-col-size=\"xl\"\u003eAnti-doping labs report \u003cstrong data-start=\"2602\" data-end=\"2623\"\u003eYK-11 metabolites\u003c\/strong\u003e enabling multi-week detection; positives tied to “SARM” products. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Drug Testing \u0026amp; Analysis\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"2731\" data-end=\"2734\"\u003e\n\u003ch2 data-start=\"2736\" data-end=\"2771\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-start=\"2773\" data-end=\"2808\"\u003e2.1 Receptor Pharmacodynamics\u003c\/h3\u003e\n\u003cul data-start=\"2809\" data-end=\"3207\"\u003e\n\u003cli data-start=\"2809\" data-end=\"2953\"\u003e\n\u003cp data-start=\"2811\" data-end=\"2953\"\u003e\u003cstrong data-start=\"2811\" data-end=\"2846\"\u003eAR partial agonist (steroidal):\u003c\/strong\u003e Binds AR, drives a \u003cstrong data-start=\"2866\" data-end=\"2906\"\u003eligand-specific co-activator profile\u003c\/strong\u003e; less classical AR transactivation than DHT.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2954\" data-end=\"3106\"\u003e\n\u003cp data-start=\"2956\" data-end=\"3106\"\u003e\u003cstrong data-start=\"2956\" data-end=\"2986\"\u003eFollistatin transcription:\u003c\/strong\u003e AR-dependent induction of \u003cstrong data-start=\"3013\" data-end=\"3020\"\u003eFST\u003c\/strong\u003e, which \u003cstrong data-start=\"3028\" data-end=\"3073\"\u003ebinds and neutralizes myostatin\/activin A\u003c\/strong\u003e, relieving SMAD2\/3 repression.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3107\" data-end=\"3207\"\u003e\n\u003cp data-start=\"3109\" data-end=\"3207\"\u003e\u003cstrong data-start=\"3109\" data-end=\"3131\"\u003eFunctional result:\u003c\/strong\u003e \u003cstrong data-start=\"3132\" data-end=\"3148\"\u003eDual pathway\u003c\/strong\u003e—AR anabolism \u003cstrong data-start=\"3162\" data-end=\"3170\"\u003eplus\u003c\/strong\u003e myostatin-pathway \u003cstrong data-start=\"3189\" data-end=\"3206\"\u003edisinhibition\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"3209\" data-end=\"3236\"\u003e2.2 Down-stream Biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"3238\" data-end=\"3646\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"3238\" data-end=\"3280\"\u003e\n\u003ctr data-start=\"3238\" data-end=\"3280\"\u003e\n\u003cth data-start=\"3238\" data-end=\"3248\" data-col-size=\"sm\"\u003ePathway\u003c\/th\u003e\n\u003cth data-start=\"3248\" data-end=\"3269\" data-col-size=\"md\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-start=\"3269\" data-end=\"3280\" data-col-size=\"sm\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"3295\" data-end=\"3646\"\u003e\n\u003ctr data-start=\"3295\" data-end=\"3401\"\u003e\n\u003ctd data-start=\"3295\" data-end=\"3330\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3297\" data-end=\"3329\"\u003eAR → FST↑ → ActRIIB\/SMAD2\/3↓\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3330\" data-end=\"3382\" data-col-size=\"md\"\u003eMyostatin blockade; hypertrophy programs released\u003c\/td\u003e\n\u003ctd data-start=\"3382\" data-end=\"3401\" data-col-size=\"sm\"\u003eSkeletal muscle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3402\" data-end=\"3478\"\u003e\n\u003ctd data-start=\"3402\" data-end=\"3424\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3404\" data-end=\"3423\"\u003emTOR\/S6K\/4E-BP1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3424\" data-end=\"3468\" data-col-size=\"md\"\u003e↑ Protein synthesis, myofiber hypertrophy\u003c\/td\u003e\n\u003ctd data-start=\"3468\" data-end=\"3478\" data-col-size=\"sm\"\u003eMuscle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3479\" data-end=\"3558\"\u003e\n\u003ctd data-start=\"3479\" data-end=\"3505\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3481\" data-end=\"3504\"\u003eFoxO → MAFbx\/MuRF1↓\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3505\" data-end=\"3538\" data-col-size=\"md\"\u003e↓ Proteolysis (anti-catabolic)\u003c\/td\u003e\n\u003ctd data-start=\"3538\" data-end=\"3558\" data-col-size=\"sm\"\u003eCatabolic stress\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3559\" data-end=\"3646\"\u003e\n\u003ctd data-start=\"3559\" data-end=\"3591\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3561\" data-end=\"3590\"\u003eRUNX2\/OSX (AR-osteoblast)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3591\" data-end=\"3638\" data-col-size=\"md\"\u003e↑ Osteoblastogenesis, mineralization markers\u003c\/td\u003e\n\u003ctd data-start=\"3638\" data-end=\"3646\" data-col-size=\"sm\"\u003eBone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"3648\" data-end=\"3651\"\u003e\n\u003ch2 data-start=\"3653\" data-end=\"3675\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-start=\"3677\" data-end=\"4077\"\u003e\n\u003cli data-start=\"3677\" data-end=\"3760\"\u003e\n\u003cp data-start=\"3679\" data-end=\"3760\"\u003e\u003cstrong data-start=\"3679\" data-end=\"3689\"\u003eRoute:\u003c\/strong\u003e Marketed only as \u003cstrong data-start=\"3707\" data-end=\"3728\"\u003eresearch-use oral\u003c\/strong\u003e material; \u003cstrong data-start=\"3739\" data-end=\"3757\"\u003eno clinical PK\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3761\" data-end=\"3895\"\u003e\n\u003cp data-start=\"3763\" data-end=\"3895\"\u003e\u003cstrong data-start=\"3763\" data-end=\"3793\"\u003eHalf-life\/bioavailability:\u003c\/strong\u003e \u003cstrong data-start=\"3794\" data-end=\"3815\"\u003eUnknown in humans\u003c\/strong\u003e; steroidal scaffold suggests \u003cstrong data-start=\"3845\" data-end=\"3867\"\u003ehepatic metabolism\u003c\/strong\u003e and high protein binding.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3896\" data-end=\"3996\"\u003e\n\u003cp data-start=\"3898\" data-end=\"3996\"\u003e\u003cstrong data-start=\"3898\" data-end=\"3924\"\u003eMetabolites\/detection:\u003c\/strong\u003e \u003cstrong data-start=\"3925\" data-end=\"3948\"\u003eUrinary metabolites\u003c\/strong\u003e are characterized for \u003cstrong data-start=\"3971\" data-end=\"3986\"\u003eanti-doping\u003c\/strong\u003e assays.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3997\" data-end=\"4077\"\u003e\n\u003cp data-start=\"3999\" data-end=\"4077\"\u003e\u003cstrong data-start=\"3999\" data-end=\"4015\"\u003eImplication:\u003c\/strong\u003e Retail dosing claims are \u003cstrong data-start=\"4041\" data-end=\"4056\"\u003eunsupported\u003c\/strong\u003e by peer-reviewed PK.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"4079\" data-end=\"4082\"\u003e\n\u003ch2 data-start=\"4084\" data-end=\"4129\"\u003e4. Pre-clinical and Translational Evidence\u003c\/h2\u003e\n\u003ch3 data-start=\"4131\" data-end=\"4153\"\u003e4.1 Cell systems\u003c\/h3\u003e\n\u003cp data-start=\"4154\" data-end=\"4282\"\u003eOriginal reports show \u003cstrong data-start=\"4176\" data-end=\"4210\"\u003eAR-dependent FST up-regulation\u003c\/strong\u003e, \u003cstrong data-start=\"4212\" data-end=\"4235\"\u003emyotube hypertrophy\u003c\/strong\u003e, and \u003cstrong data-start=\"4241\" data-end=\"4263\"\u003eSMAD2\/3 repression\u003c\/strong\u003e in myogenic cells.\u003c\/p\u003e\n\u003ch3 data-start=\"4284\" data-end=\"4305\"\u003e4.2 Animal data\u003c\/h3\u003e\n\u003cp data-start=\"4306\" data-end=\"4482\"\u003e\u003cstrong data-start=\"4306\" data-end=\"4316\"\u003eScarce\u003c\/strong\u003e publicly available in-vivo YK-11 datasets; most supportive evidence for myostatin blockade outcomes comes from \u003cstrong data-start=\"4428\" data-end=\"4463\"\u003eother FST\/ActRIIB interventions\u003c\/strong\u003e, not YK-11 itself.\u003c\/p\u003e\n\u003ch3 data-start=\"4484\" data-end=\"4504\"\u003e4.3 Human data\u003c\/h3\u003e\n\u003cp data-start=\"4505\" data-end=\"4637\"\u003e\u003cstrong data-start=\"4505\" data-end=\"4513\"\u003eNone\u003c\/strong\u003e from controlled trials. Real-world “supplement” reports are \u003cstrong data-start=\"4574\" data-end=\"4587\"\u003eanecdotal\u003c\/strong\u003e and confounded by \u003cstrong data-start=\"4606\" data-end=\"4622\"\u003eadulteration\u003c\/strong\u003e\/co-ingestants.\u003c\/p\u003e\n\u003cblockquote data-start=\"4639\" data-end=\"4813\"\u003e\n\u003cp data-start=\"4641\" data-end=\"4813\"\u003e\u003cstrong data-start=\"4641\" data-end=\"4667\"\u003eEvidence quality note:\u003c\/strong\u003e YK-11’s efficacy\/safety profile is based \u003cstrong data-start=\"4709\" data-end=\"4734\"\u003eprimarily on in-vitro\u003c\/strong\u003e biology and class inferences. \u003cstrong data-start=\"4765\" data-end=\"4813\"\u003eRobust animal and human studies are lacking.\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-start=\"4815\" data-end=\"4818\"\u003e\n\u003ch2 data-start=\"4820\" data-end=\"4853\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"4855\" data-end=\"5284\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"4855\" data-end=\"4893\"\u003e\n\u003ctr data-start=\"4855\" data-end=\"4893\"\u003e\n\u003cth data-start=\"4855\" data-end=\"4863\" data-col-size=\"sm\"\u003eField\u003c\/th\u003e\n\u003cth data-start=\"4863\" data-end=\"4875\" data-col-size=\"sm\"\u003eRationale\u003c\/th\u003e\n\u003cth data-start=\"4875\" data-end=\"4893\" data-col-size=\"sm\"\u003eCurrent status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"4908\" data-end=\"5284\"\u003e\n\u003ctr data-start=\"4908\" data-end=\"4986\"\u003e\n\u003ctd data-start=\"4908\" data-end=\"4933\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"4910\" data-end=\"4932\"\u003eSarcopenia\/frailty\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"4933\" data-end=\"4970\" data-col-size=\"sm\"\u003eAR anabolism + myostatin restraint\u003c\/td\u003e\n\u003ctd data-start=\"4970\" data-end=\"4986\" data-col-size=\"sm\"\u003eConcept only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"4987\" data-end=\"5059\"\u003e\n\u003ctd data-start=\"4987\" data-end=\"5002\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"4989\" data-end=\"5001\"\u003eCachexia\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5002\" data-end=\"5034\" data-col-size=\"sm\"\u003eAnti-catabolic + FST up-shift\u003c\/td\u003e\n\u003ctd data-start=\"5034\" data-end=\"5059\" data-col-size=\"sm\"\u003ePreclinical rationale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5060\" data-end=\"5141\"\u003e\n\u003ctd data-start=\"5060\" data-end=\"5087\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5062\" data-end=\"5086\"\u003eMuscular dystrophies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5087\" data-end=\"5117\" data-col-size=\"sm\"\u003eMyostatin pathway relevance\u003c\/td\u003e\n\u003ctd data-start=\"5117\" data-end=\"5141\" data-col-size=\"sm\"\u003eTheoretical\/indirect\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5142\" data-end=\"5205\"\u003e\n\u003ctd data-start=\"5142\" data-end=\"5159\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5144\" data-end=\"5158\"\u003eOsteopenia\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5159\" data-end=\"5183\" data-col-size=\"sm\"\u003eAR-osteoblast signals\u003c\/td\u003e\n\u003ctd data-start=\"5183\" data-end=\"5205\" data-col-size=\"sm\"\u003eIn-vitro rationale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5206\" data-end=\"5284\"\u003e\n\u003ctd data-start=\"5206\" data-end=\"5227\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5208\" data-end=\"5226\"\u003eRehabilitation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5227\" data-end=\"5265\" data-col-size=\"sm\"\u003ePotential to speed lean-mass regain\u003c\/td\u003e\n\u003ctd data-start=\"5265\" data-end=\"5284\" data-col-size=\"sm\"\u003eHypothesis only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"5286\" data-end=\"5289\"\u003e\n\u003ch2 data-start=\"5291\" data-end=\"5320\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-start=\"5322\" data-end=\"6269\"\u003e\n\u003cli data-start=\"5322\" data-end=\"5377\"\u003e\n\u003cp data-start=\"5324\" data-end=\"5377\"\u003e\u003cstrong data-start=\"5324\" data-end=\"5341\"\u003eHuman safety:\u003c\/strong\u003e \u003cstrong data-start=\"5342\" data-end=\"5353\"\u003eUnknown\u003c\/strong\u003e—no clinical datasets.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5378\" data-end=\"5540\"\u003e\n\u003cp data-start=\"5380\" data-end=\"5540\"\u003e\u003cstrong data-start=\"5380\" data-end=\"5394\"\u003eEndocrine:\u003c\/strong\u003e As an AR-active steroidal agent, expect \u003cstrong data-start=\"5435\" data-end=\"5459\"\u003eHPG-axis suppression\u003c\/strong\u003e (↓ LH\/FSH\/testosterone) with recovery taking \u003cstrong data-start=\"5505\" data-end=\"5521\"\u003eweeks–months\u003c\/strong\u003e after cessation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5541\" data-end=\"5642\"\u003e\n\u003cp data-start=\"5543\" data-end=\"5642\"\u003e\u003cstrong data-start=\"5543\" data-end=\"5554\"\u003eLipids:\u003c\/strong\u003e SARM-class pattern of \u003cstrong data-start=\"5577\" data-end=\"5588\"\u003eHDL-C ↓\u003c\/strong\u003e (± LDL\/TG ↑) is plausible—\u003cstrong data-start=\"5615\" data-end=\"5639\"\u003eno formal YK-11 data\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5643\" data-end=\"5819\"\u003e\n\u003cp data-start=\"5645\" data-end=\"5819\"\u003e\u003cstrong data-start=\"5645\" data-end=\"5657\"\u003eHepatic:\u003c\/strong\u003e \u003cstrong data-start=\"5658\" data-end=\"5674\"\u003eCase reports\u003c\/strong\u003e of hepatotoxicity exist with unregulated “SARM” products; risk for YK-11 is \u003cstrong data-start=\"5751\" data-end=\"5767\"\u003eundetermined\u003c\/strong\u003e but \u003cstrong data-start=\"5772\" data-end=\"5784\"\u003ecredible\u003c\/strong\u003e given class\/steroidal chemistry.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5820\" data-end=\"5897\"\u003e\n\u003cp data-start=\"5822\" data-end=\"5897\"\u003e\u003cstrong data-start=\"5822\" data-end=\"5850\"\u003eDermatologic\/androgenic:\u003c\/strong\u003e \u003cstrong data-start=\"5851\" data-end=\"5885\"\u003eAcne, oily skin, hair shedding\u003c\/strong\u003e possible.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5898\" data-end=\"6049\"\u003e\n\u003cp data-start=\"5900\" data-end=\"6049\"\u003e\u003cstrong data-start=\"5900\" data-end=\"5934\"\u003eMusculoskeletal (theoretical):\u003c\/strong\u003e Rapid strength gains under myostatin restraint could \u003cstrong data-start=\"5988\" data-end=\"6021\"\u003eoutpace tendon\/ECM adaptation\u003c\/strong\u003e, raising \u003cstrong data-start=\"6031\" data-end=\"6046\"\u003einjury risk\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6050\" data-end=\"6147\"\u003e\n\u003cp data-start=\"6052\" data-end=\"6147\"\u003e\u003cstrong data-start=\"6052\" data-end=\"6067\"\u003eNeuropsych:\u003c\/strong\u003e Stimulatory\/irritability\/insomnia are \u003cstrong data-start=\"6106\" data-end=\"6119\"\u003eanecdotal\u003c\/strong\u003e in uncontrolled settings.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6148\" data-end=\"6269\"\u003e\n\u003cp data-start=\"6150\" data-end=\"6269\"\u003e\u003cstrong data-start=\"6150\" data-end=\"6172\"\u003eDrug interactions:\u003c\/strong\u003e Unknown; presume \u003cstrong data-start=\"6190\" data-end=\"6208\"\u003ehepatic enzyme\u003c\/strong\u003e interactions are possible. \u003cstrong data-start=\"6236\" data-end=\"6269\"\u003eContraindicated in pregnancy.\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"6271\" data-end=\"6300\"\u003e\u003cstrong data-start=\"6271\" data-end=\"6300\"\u003eComparative safety matrix\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"6302\" data-end=\"6754\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"6302\" data-end=\"6366\"\u003e\n\u003ctr data-start=\"6302\" data-end=\"6366\"\u003e\n\u003cth data-start=\"6302\" data-end=\"6312\" data-col-size=\"sm\"\u003eConcern\u003c\/th\u003e\n\u003cth data-start=\"6312\" data-end=\"6324\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6314\" data-end=\"6323\"\u003eYK-11\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"6324\" data-end=\"6339\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6326\" data-end=\"6338\"\u003eLGD-4033\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"6339\" data-end=\"6366\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6341\" data-end=\"6364\"\u003eEnobosarm (MK-2866)\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"6385\" data-end=\"6754\"\u003e\n\u003ctr data-start=\"6385\" data-end=\"6494\"\u003e\n\u003ctd data-start=\"6385\" data-end=\"6397\" data-col-size=\"sm\"\u003eMechanism\u003c\/td\u003e\n\u003ctd data-start=\"6397\" data-end=\"6439\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6399\" data-end=\"6438\"\u003eSteroidal AR partial agonist + FST↑\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6439\" data-end=\"6466\" data-col-size=\"sm\"\u003eNon-steroidal AR agonist\u003c\/td\u003e\n\u003ctd data-start=\"6466\" data-end=\"6494\" data-col-size=\"sm\"\u003eNon-steroidal AR agonist\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6495\" data-end=\"6560\"\u003e\n\u003ctd data-start=\"6495\" data-end=\"6510\" data-col-size=\"sm\"\u003eHuman trials\u003c\/td\u003e\n\u003ctd data-start=\"6510\" data-end=\"6521\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6512\" data-end=\"6520\"\u003eNone\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6521\" data-end=\"6540\" data-col-size=\"sm\"\u003eSmall RCT (21 d)\u003c\/td\u003e\n\u003ctd data-start=\"6540\" data-end=\"6560\" data-col-size=\"sm\"\u003eMultiple Phase 2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6561\" data-end=\"6622\"\u003e\n\u003ctd data-start=\"6561\" data-end=\"6579\" data-col-size=\"sm\"\u003eHPG suppression\u003c\/td\u003e\n\u003ctd data-start=\"6579\" data-end=\"6599\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6581\" data-end=\"6598\"\u003eLikely strong\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6599\" data-end=\"6610\" data-col-size=\"sm\"\u003eModerate\u003c\/td\u003e\n\u003ctd data-start=\"6610\" data-end=\"6622\" data-col-size=\"sm\"\u003eModerate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6623\" data-end=\"6701\"\u003e\n\u003ctd data-start=\"6623\" data-end=\"6639\" data-col-size=\"sm\"\u003eLipid effects\u003c\/td\u003e\n\u003ctd data-start=\"6639\" data-end=\"6670\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6641\" data-end=\"6669\"\u003eUnknown (likely adverse)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6670\" data-end=\"6685\" data-col-size=\"sm\"\u003eHDL ↓ common\u003c\/td\u003e\n\u003ctd data-start=\"6685\" data-end=\"6701\" data-col-size=\"sm\"\u003eHDL ↓ common\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6702\" data-end=\"6754\"\u003e\n\u003ctd data-start=\"6702\" data-end=\"6722\" data-col-size=\"sm\"\u003eMyostatin pathway\u003c\/td\u003e\n\u003ctd data-start=\"6722\" data-end=\"6743\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6724\" data-end=\"6742\"\u003eDirect via FST\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6743\" data-end=\"6748\" data-col-size=\"sm\"\u003eNo\u003c\/td\u003e\n\u003ctd data-start=\"6748\" data-end=\"6754\" data-col-size=\"sm\"\u003eNo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"6756\" data-end=\"6759\"\u003e\n\u003ch2 data-start=\"6761\" data-end=\"6787\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-start=\"6789\" data-end=\"7045\"\u003e\n\u003cli data-start=\"6789\" data-end=\"6834\"\u003e\n\u003cp data-start=\"6791\" data-end=\"6834\"\u003e\u003cstrong data-start=\"6791\" data-end=\"6805\"\u003eApprovals:\u003c\/strong\u003e \u003cstrong data-start=\"6806\" data-end=\"6814\"\u003eNone\u003c\/strong\u003e (not a medicine).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6835\" data-end=\"6944\"\u003e\n\u003cp data-start=\"6837\" data-end=\"6944\"\u003e\u003cstrong data-start=\"6837\" data-end=\"6847\"\u003eSport:\u003c\/strong\u003e \u003cstrong data-start=\"6848\" data-end=\"6871\"\u003eBanned at all times\u003c\/strong\u003e (WADA S1, other anabolic agents; and as a \u003cstrong data-start=\"6914\" data-end=\"6940\"\u003enon-approved substance\u003c\/strong\u003e).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6945\" data-end=\"7045\"\u003e\n\u003cp data-start=\"6947\" data-end=\"7045\"\u003e\u003cstrong data-start=\"6947\" data-end=\"6958\"\u003eMarket:\u003c\/strong\u003e Appears on \u003cstrong data-start=\"6970\" data-end=\"6991\"\u003eresearch-chemical\u003c\/strong\u003e sites; \u003cstrong data-start=\"6999\" data-end=\"7022\"\u003epurity\/adulteration\u003c\/strong\u003e problems are frequent.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"7047\" data-end=\"7050\"\u003e\n\u003ch2 data-start=\"7052\" data-end=\"7075\"\u003e8. Future Directions\u003c\/h2\u003e\n\u003cul data-start=\"7077\" data-end=\"7731\"\u003e\n\u003cli data-start=\"7077\" data-end=\"7167\"\u003e\n\u003cp data-start=\"7079\" data-end=\"7167\"\u003e\u003cstrong data-start=\"7079\" data-end=\"7103\"\u003eFirst-in-human PK\/PD\u003c\/strong\u003e with \u003cstrong data-start=\"7109\" data-end=\"7116\"\u003eGMP\u003c\/strong\u003e material (exposure, metabolites, dose–response).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7168\" data-end=\"7361\"\u003e\n\u003cp data-start=\"7170\" data-end=\"7361\"\u003e\u003cstrong data-start=\"7170\" data-end=\"7197\"\u003eMechanistic biomarkers:\u003c\/strong\u003e \u003cstrong data-start=\"7198\" data-end=\"7261\"\u003eCirculating myostatin, follistatin, SMAD2\/3 phosphorylation\u003c\/strong\u003e, \u003cstrong data-start=\"7263\" data-end=\"7272\"\u003eIGF-1\u003c\/strong\u003e, and \u003cstrong data-start=\"7278\" data-end=\"7300\"\u003eDXA\/MRI muscle CSA\u003c\/strong\u003e; \u003cstrong data-start=\"7302\" data-end=\"7323\"\u003estrength\/function\u003c\/strong\u003e endpoints (1RM, stair-climb power).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7362\" data-end=\"7477\"\u003e\n\u003cp data-start=\"7364\" data-end=\"7477\"\u003e\u003cstrong data-start=\"7364\" data-end=\"7383\"\u003eSafety program:\u003c\/strong\u003e \u003cstrong data-start=\"7384\" data-end=\"7393\"\u003eLiver\u003c\/strong\u003e, \u003cstrong data-start=\"7395\" data-end=\"7405\"\u003elipids\u003c\/strong\u003e, \u003cstrong data-start=\"7407\" data-end=\"7429\"\u003eendocrine recovery\u003c\/strong\u003e, \u003cstrong data-start=\"7431\" data-end=\"7438\"\u003eECG\u003c\/strong\u003e, and \u003cstrong data-start=\"7444\" data-end=\"7461\"\u003etendon injury\u003c\/strong\u003e surveillance.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7478\" data-end=\"7592\"\u003e\n\u003cp data-start=\"7480\" data-end=\"7592\"\u003e\u003cstrong data-start=\"7480\" data-end=\"7503\"\u003eComparative trials:\u003c\/strong\u003e YK-11 vs \u003cstrong data-start=\"7513\" data-end=\"7536\"\u003enon-steroidal SARMs\u003c\/strong\u003e to test \u003cstrong data-start=\"7545\" data-end=\"7560\"\u003eadded value\u003c\/strong\u003e of myostatin-axis engagement.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7593\" data-end=\"7731\"\u003e\n\u003cp data-start=\"7595\" data-end=\"7731\"\u003e\u003cstrong data-start=\"7595\" data-end=\"7619\"\u003eMedicinal chemistry:\u003c\/strong\u003e Separate \u003cstrong data-start=\"7629\" data-end=\"7635\"\u003eAR\u003c\/strong\u003e and \u003cstrong data-start=\"7640\" data-end=\"7653\"\u003emyostatin\u003c\/strong\u003e activities to improve \u003cstrong data-start=\"7676\" data-end=\"7692\"\u003ebenefit–risk\u003c\/strong\u003e; explore \u003cstrong data-start=\"7702\" data-end=\"7721\"\u003etissue-targeted\u003c\/strong\u003edelivery.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"7733\" data-end=\"7736\"\u003e\n\u003ch3 data-start=\"7738\" data-end=\"7761\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-start=\"7763\" data-end=\"8473\"\u003e\n\u003cli data-start=\"7763\" data-end=\"7937\"\u003e\n\u003cp data-start=\"7765\" data-end=\"7937\"\u003eKanno Y. et al. \u003cstrong data-start=\"7781\" data-end=\"7877\"\u003eAndrogen-receptor–dependent induction of follistatin and suppression of myostatin signaling.\u003c\/strong\u003e\u003cem data-start=\"7878\" data-end=\"7935\"\u003eBiochem Biophys Res Commun; J Steroid Biochem Mol Biol.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7938\" data-end=\"8082\"\u003e\n\u003cp data-start=\"7940\" data-end=\"8082\"\u003e\u003cstrong data-start=\"7940\" data-end=\"7969\"\u003eMyogenesis \u0026amp; hypertrophy:\u003c\/strong\u003e \u003cem data-start=\"7970\" data-end=\"8012\"\u003eSkeletal Muscle; Molecular Endocrinology\u003c\/em\u003e — AR-linked myogenic differentiation and mTOR activation paradigms.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8083\" data-end=\"8166\"\u003e\n\u003cp data-start=\"8085\" data-end=\"8166\"\u003e\u003cstrong data-start=\"8085\" data-end=\"8118\"\u003eBone\/osteoblast AR signaling:\u003c\/strong\u003e \u003cem data-start=\"8119\" data-end=\"8164\"\u003eBone; Journal of Bone and Mineral Research.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8167\" data-end=\"8248\"\u003e\n\u003cp data-start=\"8169\" data-end=\"8248\"\u003e\u003cstrong data-start=\"8169\" data-end=\"8210\"\u003eCatabolic gene control (MAFbx\/MuRF1):\u003c\/strong\u003e \u003cem data-start=\"8211\" data-end=\"8246\"\u003eAJP-Endocrinology; FASEB Journal.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8249\" data-end=\"8362\"\u003e\n\u003cp data-start=\"8251\" data-end=\"8362\"\u003e\u003cstrong data-start=\"8251\" data-end=\"8277\"\u003eAnti-doping analytics:\u003c\/strong\u003e \u003cem data-start=\"8278\" data-end=\"8303\"\u003eDrug Testing \u0026amp; Analysis\u003c\/em\u003e — YK-11 metabolite identification and detection windows.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8363\" data-end=\"8473\"\u003e\n\u003cp data-start=\"8365\" data-end=\"8473\"\u003e\u003cstrong data-start=\"8365\" data-end=\"8422\"\u003eECM\/tendon considerations under myostatin modulation:\u003c\/strong\u003e \u003cem data-start=\"8423\" data-end=\"8473\"\u003eMatrix Biology; Journal of Orthopaedic Research.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":52684869763410,"sku":null,"price":90.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/yk-11_injectable.png?v=1770834965","url":"https:\/\/sciencepeptideslab.com\/products\/injectable-yk-11-700mg-vial","provider":"Science Peptides Lab","version":"1.0","type":"link"}